Zonisamid
(преусмерено са Zonizamid)
 | |
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Exceglan, Excegram, Excegran, Zonegran |
| Drugs.com | Monografija |
| Način primene | Oralno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 63 h |
| Identifikatori | |
| CAS broj | 68291-97-4  |
| ATC kod | N03AX15 (WHO) |
| PubChem | CID 5734 |
| DrugBank | DB00909 |
| ChemSpider | 5532 |
| KEGG | C07504 |
| ChEBI | CHEBI:10127 |
| ChEMBL | CHEMBL750 |
| Hemijski podaci | |
| Formula | C8H8N2O3S |
| Molarna masa | 212,226 |
| |
| |
| Fizički podaci | |
| Tačka topljenja | 161—163 °C (322—325 °F) |
Zonisamid je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 212,226 Da.[1][2][3][4][5][6][7][8][9][10][11][12]
Osobine[уреди | уреди извор]
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 1 |
| Broj rotacionih veza | 2 |
| Particioni koeficijent[13] (ALogP) | 0,4 |
| Rastvorljivost[14] (logS, log(mol/L)) | -2,2 |
| Polarna površina[15] (PSA, Å2) | 94,6 |
Reference[уреди | уреди извор]
- ^ Murata, M.; Horiuchi, E.; Kanazawa, I. (децембар 2001). „Zonisamide has beneficial effects on Parkinson's disease patients”. Neuroscience Research. 41 (4): 397—9. PMID 11755227. S2CID 41685120. doi:10.1016/s0168-0102(01)00298-x.
- ^ Gadde, K. M.; Franciscy, D. M.; Wagner Hr, 2nd; Krishnan, K. R. (2003-04-09). „Zonisamide for weight loss in obese adults: A randomized controlled trial”. JAMA. 289 (14): 1820—5. PMID 12684361. doi:10.1001/jama.289.14.1820.
- ^ Hasegawa, H. (мај 2004). „Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: A retrospective, open label, uncontrolled study in a VA hospital”. Current Medical Research and Opinion. 20 (5): 577—80. PMID 15140322. S2CID 43580909. doi:10.1185/030079904125003313.
- ^ Leppik, I. E. (2004). „Zonisamide: Chemistry, mechanism of action, and pharmacokinetics”. Seizure. 13 Suppl 1: S5—9; discussion S10. PMID 15511691. S2CID 13458791. doi:10.1016/j.seizure.2004.04.016.
- ^ Ueda, Y.; Doi, T.; Tokumaru, J.; Willmore, L. J. (2003). „Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures”. Brain Research. Molecular Brain Research. 116 (1–2): 1—6. PMID 12941455. doi:10.1016/s0169-328x(03)00183-9.
- ^ Farooq, M. U.; Moore, P. W.; Bhatt, A.; Aburashed, R.; Kassab, M. Y. (септембар 2008). „Therapeutic role of zonisamide in neuropsychiatric disorders”. Mini Reviews in Medicinal Chemistry. 8 (10): 968—75. PMID 18782051. doi:10.2174/138955708785740643.
- ^ Schulze-Bonhage, A. (јануар 2010). „Zonisamide in the treatment of epilepsy”. Expert Opinion on Pharmacotherapy. 11 (1): 115—26. PMID 20001433. S2CID 24881172. doi:10.1517/14656560903468728.
- ^ Kothare, S. V.; Kaleyias, J. (април 2008). „Zonisamide: Review of pharmacology, clinical efficacy, tolerability, and safety”. Expert Opinion on Drug Metabolism & Toxicology. 4 (4): 493—506. PMID 18433351. S2CID 71773943. doi:10.1517/17425255.4.4.493.
- ^ Peters, D. H.; Sorkin, E. M. (мај 1993). „Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy”. Drugs. 45 (5): 760—87. PMID 7686468. doi:10.2165/00003495-199345050-00010.
- ^ Sobieszek, G.; Borowicz, K. K.; Kimber-Trojnar, Z.; Małek, R.; Piskorska, B.; Czuczwar, S. J. (2003). „Zonisamide: A new antiepileptic drug”. Polish Journal of Pharmacology. 55 (5): 683—9. PMID 14704463.
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
